Anxiety and depression in the perinatal period are extremely prevalent, with approximately ten percent of pregnant women in the US suffering from perinatal depression each year. Selective Serotonin Reuptake Inhibitors (SSRIs) are one of the most commonly prescribed antidepressant classes for this time period due to their minimal side effects in comparison with others. However, they have recently been associated with various fetal malformations. Due to the stand alone risk of untreated depression and the fetal effect in pregnancy, studies are often hesitant to suggest a change in treatment, such as cessation, for those mothers taking SSRIs. Yet, over half of the women taking SSRIs at the start of their pregnancy ultimately end usage before birth, due to these potential risks. These conflicting suggestions often lead mothers in this position to be left with an unclear direction for their SSRI treatment, with fear for their child’s outcomes as well as their own mental health. This study aims to examine the fetal malformation risks for cessation of SSRI antidepressants in the 1st, 2nd, and 3rd trimester separately, in comparison with complete duration risks. Malformations involving the neurological, cardiovascular, and musculoskeletal systems would all be tested for, alongside more specific malformations; cleft palate, omphalocele, and gastroschisis. Through this study, the third trimester would be examined as a potential viable cessation time. From this study I would hope to provide further insight into safe treatment for mothers and their children in this position and further direction for research in this field.